Abbott announced the availability of its Panbio™ COVID-19 Antigen Rapid Test Device for the detection of the SARS-CoV-2 virus in adults and children, said a press release.
The rapid antigen test – which is authorized for use by healthcare professionals – requires no instrumentation and provides results in as early as 15 minutes, making it a valuable tool for testing large numbers of patients in a variety of community settings.
Abbott has the capacity to provide millions of tests to Bangladesh and has already delivered rapid antigen tests to leading government and private hospitals and labs all over the country.
“Rapid antigen tests can enable frequent COVID-19 testing at mass scale so that those who are infected can be identified quickly to help slow the spread of virus,” said Tanbir Ashraf Bhuiyan, country manager for Abbott’s rapid diagnostics business in Bangladesh.”Abbott has leveraged its leadership in infectious diseases to create a powerful tool that makes large-scale testing fast, affordable and accessible and is committed to bringing this testing to Bangladesh.”
Panbio COVID-19 Antigen Rapid Test Device is a reliable, affordable, portable and scalable option for COVID-19 testing. The rapid antigen test may also be a very useful tool for supporting public health strategies, including contact tracing and large-scale testing of people suspected of having an active infection.
